The estimated Net Worth of Der Velden Peter Lumira Cap... is at least $1.45 Milhão dollars as of 9 January 2023. Der Cap owns over 297,474 units of Edesa Biotech stock worth over $656,702 and over the last 5 years Der sold EDSA stock worth over $788,306.
Sign up
Der Cap EDSA stock SEC Form 4 insiders trading
Der has made over 2 trades of the Edesa Biotech stock since 2020, according to the Form 4 filled with the SEC. Most recently Der sold 297,474 units of EDSA stock worth $788,306 on 9 January 2023.
The largest trade Der's ever made was selling 297,474 units of Edesa Biotech stock on 9 January 2023 worth over $788,306. On average, Der trades about 87,620 units every 219 days since 2019. As of 9 January 2023 Der still owns at least 150,275 units of Edesa Biotech stock.
You can see the complete history of Der Cap stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Der Cap's mailing address?
Der's mailing address filed with the SEC is 770-141 ADELAIDE STREET WEST770-141 ADELAIDE STREET WEST, , TORONTOTORONTO, A6A6, M5H 3L5M5H 3L5.
Insiders trading at Edesa Biotech
Over the last 5 years, insiders at Edesa Biotech have traded over $856,596 worth of Edesa Biotech stock and bought 247,412 units worth $776,447 . The most active insiders traders include Der Velden Peter Lumira Cap..., Pardeep Pardeep Nijhawan Me..., eJennifer M Chao. On average, Edesa Biotech executives and independent directors trade stock every 50 days with the average trade being worth of $73,455. The most recent stock trade was executed by Pardeep Pardeep Nijhawan Me... on 25 March 2024, trading 5,000 units of EDSA stock currently worth $20,000.
What does Edesa Biotech do?
Edesa Biotech, Inc., a biopharmaceutical company, engages in acquiring, developing, and commercializing clinical-stage drugs for inflammatory and immune-related diseases with clear unmet medical needs. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in covid-19 patients; and EB01, a topical treatment that is in Phase 2B clinical study for chronic allergic contact dermatitis. It has a license agreement with NovImmune SA to develop monoclonal antibodies targeting TLR4 and CXCL10. Edesa Biotech, Inc. was founded in 2015 and is headquartered in Markham, Canada.
What does Edesa Biotech's logo look like?
Complete history of Der Cap stock trades at Edesa Biotech
Edesa Biotech executives and stock owners
Edesa Biotech executives and other stock owners filed with the SEC include:
-
Dr. Pardeep Nijhawan FRCPC, M.D.,
CEO, Company Sec. & Director -
Dr. Michael J. Brooks M.B.A., Ph.D.,
Pres -
Kathi Niffenegger CPA, CPA,
Chief Financial Officer -
Rajan Puri,
Sr. VP of Manufacturing -
Gary Koppenjan,
VP of Investor Relations & Communications -
Patrick Marshall,
-
Stephen Lemieux,
Chief Financial Officer -
Joan Chypyha,
-
Charles V Olson,
-
Lorin K Johnson,
-
Carlo Sistilli,
-
Kathi Niffenegger,
Chief Financial Officer -
Der Velden Peter Lumira Cap...,
-
Jennifer M Chao,
-
Frank R. Oakes,
-
Pardeep Pardeep Nijhawan Me...,
Chief Executive Officer -
Paul William Pay,
-
Der Velden Peter Van,
-
Sean Arthur Mac Donald,
-
Michael J Brooks,
President -
Pardeep Nijhawan,
Chief Executive Officer